Cadrenal Therapeutics (NASDAQ:CVKD) Stock Price Expected to Rise, HC Wainwright Analyst Says

Cadrenal Therapeutics (NASDAQ:CVKD) had its target price lifted by HC Wainwright from $3.00 to $32.00 in a research note issued to investors on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Cadrenal Therapeutics Trading Down 6.6 %

Shares of CVKD stock opened at $16.56 on Monday. The company has a market capitalization of $17.72 million, a PE ratio of -2.48 and a beta of 1.52. Cadrenal Therapeutics has a 1 year low of $5.40 and a 1 year high of $32.55. The company has a 50 day moving average of $13.28.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.